Evaluation of the rapid ResaPolymyxin Acinetobacter/Pseudomonas NP test for rapid colistin resistance detection in lactose non-fermenting Gram-negative bacteria

References

1. Weiner LM, Webb AK, Limbago B, Dudeck MA, Patel J et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: Summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2011-2014. Infect Control Hosp Epidemiol 2016; 37:1288–1301 [View Article] [PubMed]
   [Google Scholar]
2. European Centre for Disease Prevention and Control Incidence and Attributable Mortality of Healthcare-Associated Infections in Intensive Care Units in Europe, 2008-2012 Stockholm: European Centre for Disease Prevention and Control; 2018
   [Google Scholar]
3. Shortridge D, Gales AC, Streit JM, Huband MD, Tsakris A et al. Geographic and temporal patterns of antimicrobial resistance in Pseudomonas aeruginosa over 20 years from the SENTRY Antimicrobial Surveillance Program, 1997-2016. Open Forum Infect Dis 2019; 6:S63–S68 [View Article] [PubMed]
   [Google Scholar]
4. Rice LB. Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE. J Infect Dis 2008; 197:1079–1081 [View Article] [PubMed]
   [Google Scholar]
5. World Health Organization Global Priority List of Antibiotic-Resistant Bacteria to Guide Research, Discovery, and Development of New Antibiotics Geneva: World Health Organization; 2017
   [Google Scholar]
6. World Health Organization Prioritization of pathogens to guide research, discovery, and development of new antibiotics for drug resistant bacterial infections, including tuberculosis Geneva: World Health Organization (WHO; 2017
   [Google Scholar]
7. The US Centers for Disease Control and Prevention Antibiotic Resistance Threats in the United States, 2019 Atlanta, GA: U.S. Department of Health and Human Services, CDC; 2019
   [Google Scholar]
8. Li J, Nation RL, Turnidge JD, Milne RW, Coulthard K. Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect Dis 2006; 6:589–601 [View Article] [PubMed]
   [Google Scholar]
9. Nation RL, Li J, Cars O, Couet W, Dudley MN. Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus. Lancet Infect Dis 2015; 15:225–234 [View Article] [PubMed]
   [Google Scholar]
10. Falagas ME, Rafailidis PI, Ioannidou E, Alexiou VG, Matthaiou DK. Colistin therapy for microbiologically documented multidrug-resistant Gram-negative bacterial infections: a retrospective cohort study of 258 patients. Int J Antimicrob Agents 2010; 35:194–199 [View Article] [PubMed]
    [Google Scholar]
11. Falagas ME, Kasiakou SK. Colistin: the revival of polymyxins for the management of multidrug-resistant Gram-negative bacterial infections. Clin Infect Dis 2005; 40:1333–1341 [View Article] [PubMed]
    [Google Scholar]
12. Liu Y-Y, Chandler CE, Leung LM, McElheny CL, Mettus RT et al. Structural modification of lipopolysaccharide conferred by mcr-1 in Gram-negative ESKAPE pathogens. Antimicrob Agents Chemother 2017; 61:e00580-17 [View Article] [PubMed]
    [Google Scholar]
13. Romano KP, Warrier T, Poulsen BE, Nguyen PH, Loftis AR et al. Mutations in pmrB confer cross-resistance between the LptD inhibitor POL7080 and colistin in Pseudomonas aeruginosa. Antimicrob Agents Chemother 2019; 63:e00511-19 [View Article] [PubMed]
    [Google Scholar]
14. Trebosc V, Gartenmann S, Tötzl M, Lucchini V, Schellhorn B et al. Dissecting colistin resistance mechanisms in extensively drug-resistant Acinetobacter baumannii clinical isolates. mBio 2019; 10:e01083-19 [View Article] [PubMed]
    [Google Scholar]
15. Kallel H, Bahloul M, Hergafi L, Akrout M, Ketata W. Colistin as a salvage therapy for nosocomial infections caused by multidrug-resistant bacteria in the ICU. Int J Antimicrob Agents 2006; 28:366–369 [View Article] [PubMed]
    [Google Scholar]
16. Marchaim D, Kaye D, Kaye KS. Use of colistin in critically Ill patients. Li J, Nation R, Kaye K. eds In Polymyxin Antibiotics: From Laboratory Bench to Bedside Cham: Springer International Publishing; 2019 pp 155–179
    [Google Scholar]
17. The CLSI-EUCAST Polymyxin Breakpoints Working Group Recommendations for MIC determination of colistin (polymyxin E) as recommended by the joint CLSI-EUCAST Polymyxin Breakpoints Working Group; 2016
18. International Organization for Standardization Susceptibility testing of infectious agents and evaluation of performance of antimicrobial susceptibility test devices — Part 1: Broth micro-dilution reference method for testing the in vitro activity of antimicrobial agents against rapidly growing aerobic bacteria involved in infectious diseases. ISO 20776‐1:2019 Geneva: International Organization for Standardization; 2019
    [Google Scholar]
19. Satlin MJ. The search for a practical method for colistin susceptibility testing: Have we found it by going back to the future?. J Clin Microbiol 2019; 57:e01608-18 [View Article] [PubMed]
    [Google Scholar]
20. Tan TY, LS N. Comparison of three standardized disc susceptibility testing methods for colistin. J Antimicrob Chemother 2006; 58:864–867 [View Article]
    [Google Scholar]
21. Matuschek E, Åhman J, Webster C, Kahlmeter G. Antimicrobial susceptibility testing of colistin - evaluation of seven commercial MIC products against standard broth microdilution for Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Acinetobacter spp. Clin Microbiol Infect 2018; 24:865–870 [View Article] [PubMed]
    [Google Scholar]
22. Nordmann P, Jayol A, Poirel L. Rapid detection of polymyxin resistance in Enterobacteriaceae. Emerg Infect Dis 2016; 22:1038–1043 [View Article] [PubMed]
    [Google Scholar]
23. Lescat M, Poirel L, Tinguely C, Nordmann P. A resazurin reduction-based assay for rapid detection of polymyxin resistance in Acinetobacter baumannii and Pseudomonas aeruginosa. J Clin Microbiol 2019; 57:e01563-18 [View Article] [PubMed]
    [Google Scholar]
24. European Committee on Antimicrobial Susceptibility Testing Breakpoint tables for interpretation of mics and zone diameters 2020
    [Google Scholar]
25. Mitton B, Kingsburgh C, Kock MM, Mbelle NM, Strydom K. Evaluation of an in-house colistin NP test for use in resource-limited settings. J Clin Microbiol 2019; 57:e00501-19 [View Article] [PubMed]
    [Google Scholar]
26. Humphries RM, Ambler J, Mitchell SL, Castanheira M, Dingle T et al. CLSI Methods Development and Standardization Working Group best practices for evaluation of antimicrobial susceptibility tests. J Clin Microbiol 2018; 56:e01934-17 [View Article] [PubMed]
    [Google Scholar]
27. International Organization for Standardization Clinical laboratory testing and in vitro diagnostic test systems — Susceptibility testing of infectious agents and evaluation of performance of antimicrobial susceptibility test devices — Part 2: Evaluation of performance of antimicrobial susceptibility test devices. ISO 20776-2:2007 Geneva: International Organization for Standardization; 2007
    [Google Scholar]
28. Germ J, Poirel L, Kisek TC, Spik VC, Seme K. Evaluation of resazurin-based rapid test to detect colistin resistance in Acinetobacter baumannii isolates. Eur J Clin Microbiol Infect Dis 2019; 38:2159–2162 [View Article] [PubMed]
    [Google Scholar]
29. Jia H, Fang R, Lin J, Tian X, Zhao Y. Evaluation of resazurin-based assay for rapid detection of polymyxin-resistant Gram-negative bacteria. BMC Microbiol 2020; 20:77 [View Article] [PubMed]
    [Google Scholar]
30. Javed M, Ueltzhoeffer V, Heinrich M, Siegrist HJ, Wildermuth R. Colistin susceptibility test evaluation of multiple-resistance-level Pseudomonas aeruginosa isolates generated in a morbidostat device. J Antimicrob Chemother 2018; 73:3368–3374 [View Article] [PubMed]
    [Google Scholar]
31. Rodriguez CH, Traglia G, Bastias N, Pandolfo C, Bruni G. Discrepancies in susceptibility testing to colistin in Acinetobacter baumannii: the influence of slow growth and heteroresistance. Int J Antimicrob Agents 2019; 54:587–591 [View Article] [PubMed]
    [Google Scholar]
32. Jayol A, Nordmann P, Lehours P, Poirel L, Dubois V. Comparison of methods for detection of plasmid-mediated and chromosomally encoded colistin resistance in Enterobacteriaceae. Clin Microbiol Infect 2018; 24:175–179 [View Article] [PubMed]
    [Google Scholar]
33. Simner PJ, Bergman Y, Trejo M, Roberts AA, Marayan R et al. Two-site evaluation of the colistin broth disk elution test to determine colistin in vitro activity against Gram-negative bacilli. J Clin Microbiol 2019; 57:e01163-18 [View Article] [PubMed]
    [Google Scholar]
34. Lin J, Xu C, Fang R, Cao J, Zhang X et al. Resistance and heteroresistance to colistin in Pseudomonas aeruginosa isolates from Wenzhou, China. Antimicrob Agents Chemother 2019; 63:e00556-19 [View Article] [PubMed]
    [Google Scholar]
35. Sadek M, Tinguely C, Poirel L, Nordmann P. Rapid Polymyxin/Pseudomonas NP test for rapid detection of polymyxin susceptibility/resistance in Pseudomonas aeruginosa. Eur J Clin Microbiol Infect Dis 2020; 39:1657–1662 [View Article] [PubMed]
    [Google Scholar]
36. Singh-Moodley A, Duse A, Naicker P, Kularatne R, Nana T. Laboratory based antimicrobial resistance surveillance for Pseudomonas aeruginosa blood isolates from South Africa. J Infect Dev Ctries 2018; 12:616–624 [View Article] [PubMed]
    [Google Scholar]
37. Nyasulu PS, Murray J, Perovic O, Koornhof H. Laboratory information system for reporting antimicrobial resistant isolates from academic hospitals. J Infect Dev Ctries 2017; 11:705–718 [View Article] [PubMed]
    [Google Scholar]
38. Ramsamy Y, Essack SY, Sartorius B, Patel M, Mlisana KP. Antibiotic resistance trends of ESKAPE pathogens in Kwazulu-natal, South Africa: A five-year retrospective analysis. Afr J Lab Med 2018; 7:887 [View Article] [PubMed]
    [Google Scholar]